Pfizer revenue 2006-2023

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2022, the company's total revenue exceeded 100 billion U.S. dollars for the first time, a record among global drug manufacturers. However, in 2023, revenues dropped dramatically to around 58 billion dollars.

Pfizer’s global positioning

Pfizer’s products are available in many countries worldwide and as of 2023 the company had some 170 research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few.

Pfizer’s top products

In 2022, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.